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Background: Photochemical internalisation (PCI) is a light-triggered and site-speciﬁc technique that
enhances the delivery of therapeutic agents to their intracellular targets using amphiphilic,
photosensitizing agents. Methods: This study investigated the eﬀect that the intracellular redox
environment of 4T1 breast cancer cells exerts on PCI-facilitated delivery of the type I ribosome
inactivating protein, saporin, and the topoisomerase inhibitor, mitoxantrone, either individually or in
combination. Buthionine sulfoximime (BSO), a clinically used inhibitor of glutathione synthesis, and the
singlet oxygen scavenger, L-histidine, were used to enhance the oxidative and reductive state of the cells
respectively. Results: PCI of saporin at 30 nM was eﬀective in reducing cellular viability, which decreased
to 16% compared to “dark” controls (P < 0.01). Addition of BSO enhanced PCI eﬃcacy by a further factor
of three (P < 0.01), but addition of L-histidine completely inhibited cytotoxicity induced by PCI. The
combination of the two cytotoxic agents, saporin and mitoxantrone, with PCI, elicited 14% and 17%
reduction in cell viability (P < 0.01) compared to PCI with saporin alone and mitoxantrone alone
respectively. Combination treatment with BSO resulted in a further signiﬁcant reduction in cell viability
by 18% (P < 0.01). Conclusions: Our ﬁndings show the eﬃcacy of PCI can be manipulated and
potentiated by modifying the intracellular redox environment.Background
Drug resistance remains a major cause of treatment failure in
cancer chemotherapy. Although many mechanisms contribute
to drug resistance, poor accessibility to intracellular targets is
a signicant factor.1 Entrapment and degradation of drugs
within endolysosomes is one of the key challenges to overcome
for eﬃcient delivery to intracellular targets. This problem
applies to macromolecular therapeutics taken up via endocy-
tosis as well as smaller agents that are weak bases and
susceptible to ion-trapping following protonation within the
acidic lysosomes. Photochemical internalisation (PCI) is
a novel drug delivery platform derived from photodynamic
therapy (PDT) that can enhance the delivery of molecules that
become sequestered within endolysosomes into the cytosol.2
PCI utilises the basic principles of PDT to facilitate the release
of molecules from endolysosomal compartments and requires
three components: a photosensitiser, light (of a specic
wavelength) and molecular oxygen. Light activation of the
photosensitiser results in the formation of reactive oxygennce, University College London, London,
@ucl.ac.uk
hemistry 2019species (ROS), including singlet oxygen (1O2). Photosensitisers
used in PCI are designed to be amphiphilic, and preferentially
localise in endolysosomal membranes. The light-induced
production of ROS causes localised endolysosomal
membrane damage, facilitating the release of contents into
the cytosol so that the drug can reach its intended intracellular
target and exert its therapeutic eﬀect more eﬃciently.1 The
spatial selectivity of the therapy is preserved as “internalised”
drugs will be released to act following exposure to light
delivered focally to the target site.
PCI has been shown to enhance the in vitro and in vivo eﬃ-
cacy of many compounds including cytotoxics3,4 and immuno-
toxins5,6 in a range of experimental cancer models, as well as
gene delivery.4 PCI has also been shown to circumvent cellular
resistance to treatment using doxorubicin7 and even PDT
treatment.8 A recent in vitro study found that PCI also had
potential neuronal tissue sparing eﬀects when used to treat
a squamous cell carcinoma cell line (PCI30).9 Such a desirable
safety prole is important for PCI to be considered a suitable
addition to the clinical arena. A phase I study, which recruited
22 patients with local, advanced or metastatic solid malignan-
cies reported that disulfonated tetraphenyl chlorin mediated
PCI using bleomycin is safe and tolerable.10,11RSC Adv., 2019, 9, 25861–25874 | 25861
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View Article OnlineThe present study uses a breast cancer cell line, and there is
a growing body of preclinical data to support the use of mini-
mally invasive therapeutic options like PDT and PCI in the
treatment of breast cancer.12 There is signicant diversity when
assessing treatment response in breast cancer,13 underpinned
by genetic variations, with four main types based on expression
of combinations or absence of ER, PR and HER-2, classied by
Perou et al.14 Current treatments are based on targeting specic
genetic variations, such as hormonal agents (tamoxifen and
anastrozole) and immunological agents, e.g. HER2-blockers
(trastuzumab). However, response is oen limited by de novo
or acquired drug resistance.15 In metastatic disease, for
example, the rate of resistance to trastuzumab monotherapy is
66–88%.16–18 Thus, drug resistance remains a major cause of
failure in breast cancer chemotherapy. The phase 1 PCI trial
included four patients with cutaneous breast metastases which
became necrotic following treatment, although surrounding
normal skin remained viable, hence our choosing breast as the
exemplar cancer in this study.
Two light exposure strategies for PCI with respect to the
timing of drug administration have been devised:19 (1) “light
aer” drug delivery – when cells are pre-treated with photo-
sensitiser and drug internalised prior to light application; and
(2) “light before” drug delivery – when cells are pre-treated with
photosensitiser and light, before the administration of the
drug. In this study we assessed how manipulating the reducing
capacity of the intracellular environment in breast cancer cells
aﬀected the eﬃciency of PCI using the aforementioned light
exposure strategies. The two diﬀerent approaches used to
manipulate the redox environment within a PCI setting were: (i)
buthionine sulfoximine (BSO), a synthetic amino acid that
irreversibly inhibits gamma-glutamylcysteine synthetase, the
enzyme required in the rst step of glutathione synthesis;20 (ii)
L-histidine (LH), a naturally occurring amino acid that has been
shown to interfere with redox reactions by scavenging hydroxyl
radicals and 1O2,21 and superoxide dismutase. Administration
of BSO attenuates intracellular levels of the reducing agent
glutathione (GSH), thereby increasing susceptibility to oxidative
damage, whereas L-histidine acts to inhibit oxidative damage. In
addition by inhibiting GSH production, BSO has been shown to
suppress the activity of glutathione peroxidases (GPXs),
including GPX4,22 which are a group of phospholipid hydro-
peroxidases that can protect a cell from lipid peroxidation.
GPX4 has been shown to play a central role in ferroptosis,22
which is a form of non-apoptotic cell death mediated by iron-
dependent ROS. The native activity of the GPXs has been
shown to be dependent on GSH, which acts as an essential
cofactor.23 BSO has also been shown to partially reverse drug-
resistance in MRP1 – overproducing cells associated with
decreased levels of GSH and increased intracellular accumula-
tion of daunorubicin.24
The study employed a standard PCI photosensitiser, disul-
fonated meso-tetraphenylporphyrin (TPPS2a) [4, 7] for PCI of
saporin, a cytotoxic 37 kDa type II ribosome inactivating
protein, alone and in combination with the topoisomerase
inhibitor, mitoxantrone (MTX), a clinically used chemothera-
peutic. Although mitoxantrone is a small molecule, it is a weak25862 | RSC Adv., 2019, 9, 25861–25874base and is prone to entrapment in acidic lysosomes. We have
previously studied PCI of this agent in multidrug resistant
breast and bladder cancer cell lines.3 The potential of PCI as
a vehicle for the targeted delivery of more than single agent
cytotoxins is particularly relevant when considering the trans-
lational capacity of PCI to the clinical arena where dual or
multiple therapies are commonplace in cancer treatment
regimens.
Experimental
Cell culture
The 4T1 murine mammary adenocarcinoma cell line stably
transfected with the rey luciferase gene (Luc2) (Caliper Life
Sciences, UK) was used throughout. The Luc2 transfection
allows bioluminescent imaging; therefore, in addition to in vitro
investigations it has capacity for future work in in vivo pre-
clinical models.25,26 Cells were maintained in Roswell Park
Memorial Institute medium (RPMI-1640) supplemented with
10% (v/v) fetal calf serum (FCS) in a humidied atmosphere of
5% CO2/air, 37 C. Cultures at <90% conuence were routinely
trypsinised (1 mg ml1 in 0.2% phosphate-buﬀered saline
(PBS)/EDTA) for propagation. For experimentation, cells were
seeded at 10 000 cells/100 ml per well into 96-well plates (Nunc,
Roskilde, Denmark).
Drugs and reagents
The photosensitizer TPPS2a (disulfonated meso-tetraphenylpor-
phine, Frontier Scientic Inc.) was dissolved in dimethyl sulf-
oxide (DMSO) and stored at 40 C, in the dark, until use. The
chemotherapeutics saporin (SAP) andmitoxantrone (MTX) were
stored at 4 C. All other reagents were purchased from Sigma-
Aldrich, UK unless otherwise stated. The redox reagents L-
histidine (LH), buthionine sulfoximine (BSO) and bovine
superoxide dismutase (SOD), were dissolved in PBS and stored
at 4 C.
Cell viability was assessed using the 3-[4,5-dimethylthiazolyl]-2,5-
diphenyltetrazolium bromide MTT assay. Absorbance of the
reduced derivative formazan at 570 nm, proportional to mito-
chondrial activity, was used as a measure of cell viability, read on
a multiwall plate reader (ELx800 Biotek 4, Bedfordshire, UK).
Photochemical internalisation (PCI) and photodynamic
therapy (PDT)
The terms used throughout are: PDT for TPPS2a-alone, without
chemotherapeutics and PCI for TPPS2a plus chemotherapeutic
agents. The PCI experiments followed either a conventional
“light aer” or “light before” protocol. In “light aer” experi-
ments, plates of cells were incubated for 24 hours under dark
(non-illuminated) conditions. At this time medium was
removed and replaced with fresh medium containing concen-
trations of SAP (15 or 30 nM), MTX (0.4 mg ml1) or TPPS2a (0.3
or 0.6 mg ml1), either alone or in combination, for 24 hours.
This ensured that in addition to PCI wells, the experiment
included a control PDT group exposed to TPPS2a, alone. Aer 24
hours, cells were washed (twice with photosensitizer andThis journal is © The Royal Society of Chemistry 2019
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View Article Onlinecytotoxin free PBS) and received fresh medium. Plates were
either illuminated immediately or 4 hours later to investigate
the impact of time delay between washing oﬀ the drugs and
exposure to light. Cells were exposed to a variety of illumination
times (60, 90, 120, 150, 180, 240 or 300 seconds), using the
Lumisource™ illuminator with peak output at 420 nm (mean
uence 7mW cm1,2 PCI Biotech, Oslo, Norway), so that 120 s at
7 mW cm2 was equivalent to 840 mJ cm2, to activate TPPS2a
using its strong blue absorption band. Following illumination,
the cells were incubated for a further 24 or 72 hours and
viability was assessed using the MTT assay.
The “light before” PCI protocol necessitates incubation and
illumination of the photosensitizer prior to exposure to
chemotherapeutics. Cells were plated and then incubated
under dark conditions for 24 hours. At this time wells destined
to receive PCI or PDT were incubated with TPPS2a (0.3 or 0.6 mg
ml1) for a further 24 hours. Cells were then washed, media
replaced, and plates were exposed to light (as above). Subse-
quently media was refreshed (for PDT wells, no cytotoxin added)
or incubated with varying concentrations of SAP (15 or 30 nM)
or MTX (0.4 mg ml1) for PCI-treatment wells. Aer a 24 hours
incubation, the medium was replaced by cytotoxin-free medium
incubated for a further 24 hours and viability was assessed
using the MTT assay.
All PCI and PDT experiments were carried out under dark
conditions and plates wrapped in aluminium foil during incu-
bation to avoid unwanted TPPS2a photoactivation. Cells that
were not illuminated or exposed to light are referred to as ‘dark’
controls throughout experimentation. Pilot PDT and PCI
studies were initially performed to determine the optimum
variable ranges, namely the photosensitizer and light dosing,
and the cell washing or ‘chasing’ prior to illumination. TheMTT
viability assays was applied in these dose-ranging studies at 24 h
following exposure to light, and illumination times (light doses)
between 60–300 s were investigated.
To determine the eﬀect of washing oﬀ the photosensitizer or
‘chasing’, which is well documented in the literature on PCI,2
two treatment sequences were investigated. The rst (‘imme-
diate’) group comprised cells treated with TPPS2a and SAP and
illuminated immediately aer drugs were washed oﬀ at 24 h. In
the second (‘4 hour’) group cells were incubated in media alone
for 4 hours aer drug was washed oﬀ prior to illumination. The
‘immediate’ protocol, for both PDT and PCI, yielded light dose
dependent cytotoxicity up to 180 s. In comparison, cells in the ‘4
hour’ protocol group consistently exhibited statistically signi-
cant increased cell kill for PCI versus PDT: 12% at 60 seconds (P
< 0.01), 27% at 150 seconds (P < 0.01). Therefore, the majority of
subsequent experiments were carried out following a 4 hour
washout period.Combination PCI
“Combined PCI” investigations utilized co-incubation of SAP
and MTX at lower concentrations to elicit superior killing than
delivery of either chemotherapeutic by PCI alone. “Light before”
PCI and “light aer” PCI experimental protocols were tested as
described above; however, “PCI combo”wells were co-incubatedThis journal is © The Royal Society of Chemistry 2019with both 15 nM SAP and 0.4 mg ml1 MTX either before or aer
illumination depending on protocols. Cell viability was
assessed using the MTT assay.
Redox reagent enhanced or attenuated PCI and PDT
The eﬀect of potentiating or attenuating cellular levels of reac-
tive oxidation species on the eﬃcacy of PCI and PDT was
investigated using BSO, or SOD and LH respectively. “Light
before”, “light aer” and combined PCI protocols were
employed as above. However, one of the redox reagents was
added throughout drug incubation, illumination and recovery,
at the following concentrations: 1.0 mg ml1 BSO, 20, 40 or 80
mM L-histidine and 100 U SOD. Cells were washed twice to
ensure removal of residual redox reagents before cell viability
was determined using the MTT assay.
Confocal microscopy
1  104 4T1 (murine) breast cancer cells were seeded in 35 mm
diameter glass-bottomed Fluorodishes™ (WPI, UK) and were
incubated for 48 hours in full medium (as above) to encourage
optimal adherence and sub-conuent cell spreading for
imaging. Cells were imaged using an inverted Olympus Fluo-
view 1000 confocal laser-scanning microscope. Fluorescence
confocal images were obtained using a 60  1.35 NA oil
immersion or a 20  0.75 NA objective. ImageJ soware (NIH
open source) was used to analyze images and obtain mean
intensities for delineated regions of interest.
Cells were incubated with MTX, SAP, TPPS2a or a combina-
tion thereof for 24 hours and subsequently washed with PBS
and incubated in fresh medium for a further 4 hours. At this
point, cells were illuminated with blue light (Lumisource™)
and imaged aer 4 h. Intracellular glutathione expression (in
the presence/absence of BSO exposure) was determined by the
addition of monochlorobimane (mBCl) which becomes uo-
rescent when conjugated to low molecular weight thiols
including glutathione.27–29 The absorption/emission maximum
for the glutathione–monochlorobimane conjugate was 394/
490 nm (Life Technologies, Molecular Probes®, UK). Cells
(BSO incubation) were treated with 40 mM mBCl (in RPMI-
1640) for 20 minutes prior to confocal microscopy.29
To assess the impact of ROS production on lipid perox-
idation, the lipophilic BODIPY® C11 reagent was used as
a uorescence probe (Image-iT® Peroxidation Kit, Life Tech-
nologies, Molecular Probes®, UK). The probe was prepared
according to the manufacturers guidelines and added at
a concentration of 10 mM to treated cells, as described above, 30
minutes prior to confocal imaging. The following combinations
of excitation/detection wavelengths were used for uorescence
microscopy: for the reduced form 559/590 nm, for the oxidized
form 488/520 nm. Both emission bands are at shorter wave-
lengths than the porphyrin uorescence which has peak emis-
sion at 660 nm.
Statistical analysis
Unless otherwise indicated, all experiments were repeated
a minimum 4 times. For graphical representations, eachRSC Adv., 2019, 9, 25861–25874 | 25863
Fig. 1 Monochlorobimane–glutathione detection in breast cancer
cells. 4T1 cancer cells were treated with mBCl 4 mM for 20 minutes,
prior to confocal microscopy either (A) alone or (B) following 24 h
incubation with BSO, 1.0 mg ml1; 20 objective, scale bar is 20
microns.
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View Article Onlineexperimental value is the average of a 16 well data set. Results
are presented as mean values  standard deviation, and data
were analysed using one-way ANOVA with appropriate post-hoc
analysis, e.g., Tukey's for experiments using combinations of
diﬀerent agents. For images, quantitative data, i.e., those
generated from uorescent intensity evaluation (e.g., ImageJ),
were analysed using T-tests and/or one-way ANOVA with post-
hoc analysis, e.g., Tukey's. Signicance was set at P < 0.05.
Specic P values are shown within gure legends and/or
described in results, as appropriate.
To evaluate whether a synergistic interaction between the
two separate therapies applied, we used the following equation
to calculate the value of alpha (a):
a ¼ survival fraction ðPDTÞ  survival fraction ðcytotoxinÞ
survival fractionðPCIÞ
The numerator represents the fractional viability for each
separate therapy (i.e. PDT using TPPS2a and cytotoxin). The
denominator represents the fractional viability observed
following the PCI combination treatment. If a > 1 then a syner-
gistic eﬀect has been observed whereas an antagonistic eﬀect is
denoted by a < 1. This analysis has been used previously to
identify synergistic eﬀects in PCI.30
Results
The eﬀects of the glutathione synthase inhibitor, buthionine
sulfoximine, in combination with PDT or PCI were studied in
the 4T1 breast carcinoma cell line to test our hypothesis that
treatment with BSO would enhance PCI treatment eﬃcacy. Prior
to these studies we sought to demonstrate that treatment of the
4T1 cells with low concentrations of BSO could inuence the
intracellular levels of glutathione. Since enhanced cytotoxicity
using PCI of saporin is triggered by sub-lethal PDT, we also
studied the eﬀect of BSO on the PDT response.
Confocal studies: eﬀect of buthionine sulfoximine on
intracellular glutathione expression
The eﬀect of buthionine sulfoximine (BSO) on the expression of
intracellular reduced glutathione (GSH) stores in 4T1 cells was
assessed by detection of the GSH uorescence probe mono-
chlorobimane (mBCl), under confocal microscopy (Fig. 1). Using
quantitative image analysis, a four-fold reduction in themBCl signal
in cells treated with BSO compared to controls was observed (P <
0.001), which is consistent with a signicant drop in intracellular
GSH levels and hence alteration of the redox environment.
Eﬀect of lower glutathione levels on PDT
The eﬀect of the glutathione synthase inhibitor, BSO, on PDT
was determined when cells were illuminated either immediately
(Fig. 2A) or 4 h (Fig. 2B) aer washing oﬀ the photosensitiser.
Cells treated by PDT utilising the ‘immediate’ protocol,
across the range of durations of illumination demonstrated no
signicant diﬀerences between PDT versus PDT + BSO (Fig. 2A).
In contrast, there was marked diﬀerence in cytotoxicity of cells25864 | RSC Adv., 2019, 9, 25861–25874exposed to PDT utilising the ‘4 hour’ washout or chasing
protocol, which is the same protocol used for subsequent PCI
studies. Viability loss from addition of BSO alone was negli-
gible. Cells exposed to illumination durations $150 s exhibited
a signicantly enhanced increase in cytotoxicity when exposed
to BSO + PDT compared to PDT alone. The greatest diﬀerence
was seen aer 240 seconds of illumination, from 74% viability
for the PDT group to 13% viability for the PDT + BSO group,
which reects an increase in cell kill of 61% (P < 0.01, Fig. 2B).
In the absence of light, the addition of BSO (1.0 mM) caused no
signicant change in cytotoxicity compared to ‘dark’ PDT alone.
However, with illumination, BSO alone killed up to 6% of cells,
though given the mechanism of MTT this may represent a reduc-
tion in cell metabolism (results for BSO alone not shown).Buthionine sulfoximine enhanced PCI
The eﬀect of BSO on PCI (TPPS2a + SAP) was initially investi-
gated with illumination taking place aer the 4 h chasingThis journal is © The Royal Society of Chemistry 2019
Fig. 2 Impact of Buthionine Sulfoximine on TPPS2a-mediated
Photodynamic Therapy. 4T1 breast cancer cells treated with TPPS2a,
0.6 mg ml1, alone. (A) Cells illuminated immediately after TPPS2a
washed oﬀ, with (blue line) or without (black line) BSO, 1.0 mg ml1; (B)
cells illuminated 4 h after TPPS2a washed oﬀ, with (orange broken line)
or without (black broken line) BSO, 1.0 mg ml1. Cells were illuminated
up to 300 s. Cell viability was measured using the MTT assay, 24 h after
illumination. Signiﬁcant cell kill (P < 0.01) was shown for all groups
>150 s illumination in 2B.
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View Article Onlineperiod (the light-aer protocol), with the MTT assay carried out
at 24 h aer illumination. Since PCI is designed to be triggered
by sub-lethal PDT, dose ranging pilot studies were carried out to
establish the optimum light and photosensitiser doses, with
TPPS2a concentrations at 0.3 to 0.6 mg ml
1, and illumination
times up to 300 s. The dose of saporin used alone (30 nM), had
a negligible reduction in viability (<5%) without light. These
results showed that illumination times larger than 150 s resul-
ted in signicant cell kill (p < 0.01 for all) and were therefore
unsuitable for our purpose. A combination of 120 s illumination
and 0.6 mg ml1 TPPS2a induced a 17% mean reduction in
viability (Fig. 2B), which was deemed suitable for subsequent
PCI studies. We also carried out measurements at 72 hours post
illumination and demonstrated a higher level of cell kill, with
generally all groups showing a reduction in viability, corre-
sponding to increased cell death from 24 hours to 72 hours post
treatment (not shown). Fig. 3 shows the PCI response with and
without addition of BSO for a range of illumination times usingThis journal is © The Royal Society of Chemistry 2019the 24 h time-point, and a more detailed comparison at a xed
light dose (120 s) of the data obtained using each time-point. At
72 h aer light exposure without addition of BSO, the mean
viability of the cells treated with PCI was measured as 16%
compared to 43% at 24 hours, corresponding to 2.7-fold higher
toxicity (P < 0.01). At 72 hours (no BSO), PCI as a treatment was
muchmore eﬀective than either PDT alone (TPPS2a) or cytotoxin
alone (SAP), by 4.7-fold and 5.2-fold (P < 0.01). The corre-
sponding alpha values exceed one (a ¼ 1.5 and 3.8 respectively)
which is consistent with a synergistic interaction between PDT
and saporin.
Addition of BSO to the PCI protocol resulted in the highest
cell kill. At 72 hours, the mean viability of the cells treated with
PCI + BSO was measured as 5% compared to 30% at 24 hours,
which is equivalent to 25% increased cell kill reaching a total of
95% cell kill compared to the control (P < 0.01). Comparison of
the two treatment regimens (PCI at 72 hours, versus PCI + BSO at
72 hours), there is a statistically signicant reduction in viability
in the latter group (11% diﬀerence, P < 0.01) corresponding to
a three-fold reduction in viability to give >95% viability loss with
addition of BSO.PCI: combination chemotherapy (saporin and mitoxantrone)
The administration of multiple therapeutic agents is oen uti-
lised in clinical oncology. 4T1 cells underwent PCI of a combi-
nation of anti-cancer agents, saporin and mitoxantrone, to
assess whether this would enhance cell kill compared to PCI of
each agent alone. Additionally, the eﬀect on cell viability of the
addition of BSO to the treatment protocols was evaluated. Two
regimens were compared: (1) standard “light ‘aer”’ and (2)
“light ‘before”’ chemotherapy PCI. SAP and/or MTX was added
to the appropriate treatment groups either preceding (light
‘aer’) or following (light ‘before’) illumination.
Overall, combination PCI was more eﬀective than single
agent PCI, and more eﬀective than the co-administration of the
two agents without PCI (Fig. 4A). This was evident at 24 hours
post-illumination, where in the light ‘aer’ (LA) group, combi-
nation (SAP + MTX)-PCI (Combo-PCI) was associated with 14%
and 17% reduction in cell viability (P < 0.01, a ¼ 0.70 and 1.5)
compared to SAP-PCI andMTX-PCI respectively (Fig. 4A). In line
with the results presented above, the eﬀect at 72 hours was
more pronounced, with a 19% reduction in cell viability
observed for Combo-PCI at 72 h compared to 24 h (P < 0.01 for
both; Fig. 4A). In the light ‘before’ (LB) group, Combo-PCI did
not signicantly increase cytotoxicity compared to SAP-PCI,
although MTX-PCI toxicity was enhanced by 15% (P < 0.01,
a ¼ 1.28; Fig. 4B). Overall, Combo-PCI was more eﬀective with
the LA protocol, which produced 15% increased cytotoxicity
compared to the LB protocol.
The addition of BSO generally potentiated PCI toxicity for
both Combo-PCI and single agent PCI. Addition of BSO to
Combo-PCI using the LA protocol had the best and most
consistent outcome in terms of toxicity: it resulted in an 18% (P
< 0.01, a ¼ 2.58; Fig. 4A) reduction in cell viability compared to
Combo-PCI (24 h). Finally, BSO-enhanced Combo-PCI (LA)
produced 34% reduction in viability (P < 0.01, a ¼ 3.85)RSC Adv., 2019, 9, 25861–25874 | 25865
Fig. 3 Impact of buthionine sulfoximine (BSO) on TPPS2a-mediated photochemical internalisation of saporin. 4T1 breast cancer cells treated
with TPPS2a 0.6 mg ml
1 + SAP 30 nM (PCI). (A) Cells illuminated for increasing periods up to 300 s with (orange broken line) or without (black
broken line) BSO 1.0 mg ml1. MTT assay performed 24 h after illumination; (B) Histogram of PCI + BSO data shown in (A) for comparative
purposes. All groups with illumination >150 s demonstrate signiﬁcant killing (P < 0.01); (C) cells were treated with TP or SAP or BSO alone or in
combination and illuminated for 120 s and MTT viability assay was performed 24 h (white histogram) or 72 h (red striped) after illumination.
Addition of BSO, enhanced SAP-PCI cytotoxicity by 11% at 72 h and a three-fold reduction in viability (P < 0.01) resulting in >95% cell kill
(*designates P < 0.01).
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View Article Onlinecompared to the combination of the non-PCI control (i.e. all
agents BSO/Sap/MTX). Using the LB protocol, addition of BSO to
Combo-PCI did not potentiate cytotoxicity, however, it did result
in increased cytotoxicity for single agent PCI with a 12% and
18% increase in cytotoxicity respectively (P < 0.01, SAP-PCI and
MTX-PCI).
Confocal study: lipid peroxidation
The eﬀect of ROS generation on lipid peroxidation was studied
using a lipid peroxidation uorescence probe (BODIPY® C11),
which localizes throughout lipid membranes within a cell.
Unsaturated lipids are especially prone to damage by singlet
oxygen to form lipid hydroperoxide intermediates. Following
oxidation of the probe, there is a shi in peak uorescence
emission from 590 nm (red channel) to 510 nm (green
channel – the oxidized form). As both forms of BODIPY® C11
are spectrally well separated, this property can be used to
quantify the fractions of oxidized and non-oxidized probe using
a uorescence ratio assay with confocal microscopy.31 A lower
red to green intensity ratio therefore corresponds to a higher25866 | RSC Adv., 2019, 9, 25861–25874degree of oxidation and vice versa. The fraction of oxidized
probe (i.e., the fractional oxidation) is then estimated from the
ratio of green intensity/(red intensity + green intensity).
4T1 cells were initially treated with SAP, TPPS2a and BSO
either alone or in diﬀerent combinations  light (as per 4 h PCI
protocol). Fig. 5 illustrates the impact of TPPS2a on the degree of
intracellular lipid peroxidation in the 4T1 cells under both
‘dark’ conditions (Fig. 5A) and following 150 seconds of illu-
mination (Fig. 5B). This period of illumination was selected on
the basis of the results shown in Fig. 2 and 3 which correspond
to a sub-lethal dose relevant to PCI. Ratios of the two emission
peaks were compared across the same groups of cells, as shown
in Table 1. For control cells under ‘dark’ conditions, the red
uorescence channel signal was 3.4-fold more intense than the
green signal, and the green : red channel intensity ratio was
1 : 3.4. Following illumination of 150 seconds, there was
a marked diminution of the ratio between red and green signal
intensities (Fig. 5B) with comparable intensities instead
observed for both channels. The values calculated for the frac-
tional oxidation following illumination increased from 0.23 toThis journal is © The Royal Society of Chemistry 2019
Fig. 4 Combination PCI treatment studies. 4T1 breast cancer cells
were incubatedwith diﬀerent combinations of TPPS2a 0.6 mgml
1, SAP
15 nM, MTX 0.4 mg ml1 and BSO 1.0 mg ml1. To administer PCI, cells
were illuminated for 120 s, according to the light “before” or light
“after” protocol with cell viability measured using MTT assay 24 h or
72 h after illumination. (A) Cells were treated with photosensitiser or
SAP or MTX alone or in various combinations  BSO and illuminated
for 120 s using the light ‘after’ protocol; MTT viability study performed
24 h (white histogram) or 72 h (red striped) after illumination; (B) SAP
and/or MTX was added to the appropriate treatment groups either
preceding (light ‘after’) or following (light ‘before’) illumination. There
were signiﬁcant statistical diﬀerences between all 24 h and 72 h
treatments (4A) and all (apart from APS-PCI) light ‘before’ and light
‘after’ groups, which are not designated on the graphs, to avoid clut-
tering. Also note that the control values for PDT and BSO only with/
without light that are shown in Fig. 3 also apply to this ﬁgure but are
omitted for the sake of clarity (* designates P < 0.01).
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View Article Online0.53 (Table 1). The combination of BSO + SAP resulted in
a green : red channel ratio of 1 : 1.9, corresponding to a frac-
tional oxidation value of 0.34, which is higher than control
levels. Addition of SAP alone gave the same result as the control.
The eﬀect of PCI [TPPS2a + SAP + BSO + light (150 s)] on the cells
is shown in Fig. 6A. A ratio of 1 : 1.9 (green : red channels),
equivalent to that seen with BSO + SAP was observed. However,
it is important to note that the maximum green signal was 36%
greater than that observed with BSO + SAP (P < 0.01). Fig. 6B
shows a smaller group of 4T1 cells that appear distressed aer
the same treatment regimen. These cells have a signicantlyThis journal is © The Royal Society of Chemistry 2019greater intensity of both green and red signals, compared to the
other confocal images, and appear to be undergoing the early
phases of cell death. The ratio of green : red was 1 : 1.5, thus
indicating a signicant increase in lipid peroxidation compared
to untreated controls.
The ratios of the red (non-oxidised form) divided by green
(oxidized form) intensities and the fraction of oxidized probe
are presented. Values were calculated as described in text from
Fig. 5 and 6. The PDT dark control reading is with photosen-
sitizer only, no light.Eﬀect of enhanced intracellular reducing capacity induced by
ROS scavengers
The eﬀects of ROS scavenging, using L-histidine (LH), on the
therapeutic eﬃcacy of PCI were investigated. Fig. 7 shows the
response of increasing doses of LH (10–80 mM), incubated 24 h
pre- and 24 h post-illumination, on the PCI cytotoxicity. A dose
dependent inhibition of PCI-induced cell kill was observed.
This ranged from 27% inhibition for LH (10 mM) to 51% for 80
mM (all at P < 0.01). The latter completely inhibited PCI induced
cytotoxicity with no statistically signicant diﬀerence from
control values. Interestingly no signicant reversal eﬀect was
seen for PDT + LH even at 80 mM (data not shown) although
there is only limited cell kill induced by PDT alone. The eﬀect of
SOD was also investigated, using the standard light ‘aer’
protocol (TPPS2a 0.6 mg ml
1 + SAP 30 nM + light (180 s)  SOD
at 100U). Cells treated by PCI with SOD at 100 U, 24 h pre- and
24 h post-illumination, showed a 43% inhibition (P < 0.01) in
cytotoxicity, compared to PCI alone. SOD at 100U had no
signicant eﬀect on PDT-induced cytotoxicity (data not shown).Discussion
Photochemical internalisation employs sub-lethal photody-
namic therapy to enhance the delivery of bioactive agents that
are prone to sequestration in endosomes and lysosomes. In
both PDT and PCI, the activation of a photosensitizer leads to
the formation of ROS including singlet oxygen (1O2) superoxide
anions (O2
c and OHc). The cellular phospholipid membrane
and organelle membranes are key targets of PDT since they are
rich in polyunsaturated fatty acids (PUFA), which readily react
with 1O2, to generate lipid hydroperoxide intermediates.
Superoxide and its protonated form ðHO2Þ can also oxidize
membrane components directly,32 or indirectly via its rapid
reaction with intracellular nitric oxide to generate the powerful
oxidant, peroxynitrite. The subsequent decomposition of the
lipid hydroperoxides results in the generation of ROS such as
peroxyl radicals. Wagner and colleagues33 reported that the
sensitivity of PUFAs to oxidative damage increases with the
number of double bonds per fatty acidmolecules, thus themore
unsaturated a fatty acid the greater the reducing power it
possesses. Of particular importance when considering the eﬀect
of photosensitiser mediated ROS generation in the membranes
of organelles is the fact that 30–80% of the mass of the bio-
logical cell membrane is made up of lipids. PCI represents
a developmental step of PDT, retaining its fundamentalRSC Adv., 2019, 9, 25861–25874 | 25867
Fig. 5 Lipid peroxidation imaging using confocal microscopy after PDT treatment. 4T1 breast cancer cells were incubated with TPPS2a 0.6 mg
ml1 alone (PDT) for 24 h before washing and a 4 h incubation period with fresh medium without photosensitizer. (A) Control cells without light
exposure; B cells were illuminated for 150 s. The lipid peroxidation probe was added to the cells at 10 mM and incubated at 37 C for 30 minutes.
Top right shows control cells in red channel, top left in green channel, bottom left shows merged channels and bottom right shows white light
image. (B) A signiﬁcant increase (P < 0.01) in green ﬂuorescence corresponding to oxidised lipid was observed in the illuminated group compared
to ‘dark’ control A. 60 objective, scale bar shown is 20 microns.
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View Article Onlineproperties of light, photosensitizer and oxygen dependent ROS
production, but with the eﬀect restricted to subcellular
domains,34–36 in particular, the phospholipid membranes ofTable 1 Ratio analysis of lipid peroxidation ﬂuorescence probe
(BODIPY® C11) for each treatment
Treatment
Ratio of red : green
intensities
Fractional
oxidation
PDT dark control 3.4 0.23
PDT 0.9 0.53
BSO + SAP 1.9 0.34
PCI + BSO 1.5 0.4
25868 | RSC Adv., 2019, 9, 25861–25874endosomes and lysosomes. Localized ROS production within
a lipid rich environment facilitates the production of lipid
hydroperoxides, particularly when antioxidant capacity is
overwhelmed.37
By interrogating the relationship between photosensitizer
activation in PCI and the intracellular redox environment of
a cell, we investigated whether it would be possible to form
a greater understanding of the inuence of reactive oxygen
species (ROS) production on PCI and optimize its eﬃcacy. The
main aim of this study was to investigate the eﬀect that the
intracellular redox environment exerts on the eﬃcacy of PCI-
facilitated drug delivery of SAP and/or MTX. The experimentsThis journal is © The Royal Society of Chemistry 2019
Fig. 6 Lipid peroxidation imaging using confocal microscopy after PCI treatment. 4T1 breast cancer cells were incubated with TPPS2a 0.6 mg
ml1 + SAP 30 nM+ BSO 1.0 mgml1 for 24 h before washing and a 4 h incubation period with freshmediumwithout addition of the compounds.
Cells in were then illuminated for 150 s and the lipid peroxidation probe was added to the cells at 10 mM and incubated at 37 C for 30 minutes.
Top right shows control cells in red channel, top left in green channel, bottom left showsmerged channels (mainly yellow due to combination of
red and green colours) and bottom right shows white light image. (A) Cluster of viable cells (B) small cluster of cells with distorted cell membranes
and nuclear appearance consistent with cellular distress. A signiﬁcant increase (P < 0.01) in green ﬂuorescence corresponding to oxidised lipid
was observed compared to ‘dark’ controls. 60 objective, scale bar shown is 20 microns.
This journal is © The Royal Society of Chemistry 2019 RSC Adv., 2019, 9, 25861–25874 | 25869
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Fig. 7 Eﬀect of L-histidine (LH) on photochemical internalisation of saporin. TPPS2a 0.3 mg ml
1 + SAP 15 nM + light (90 seconds)  LH
(increasing doses up to 80 mM). All LH groups showed signiﬁcant reversal of the PCI eﬀect with a maximum of 51% for LH 80 mM (P < 0.01; not
designated on the graph). 4T1 cell viability measured using MTT assay 72 h after illumination. Controls shown are with TPPS2a, but without light.
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View Article Onlineperformed were designed to initially determine whether or not
TPPS2a based PCI could be used to enhance the delivery and
consequently the cytotoxic eﬃcacy of two cytotoxic agents (SAP
and MTX). The balance between oxidation and reduction is vital
to the normal functioning of a cell and abnormal redox states
have been shown to confer resistance to cytotoxic agents in
cancer chemotherapy.38 The reducing capacity of a cell is
determined by the expression of reducing agents/enzymes
including glutathione (GSH), glutathione peroxidase (GSHPx),
catalase and superoxide dismutase (SOD), relative to the
oxidative load. These reducing agents act to prevent the toxic
and mutagenic eﬀects of ROS, for example, SOD catalyzes the
conversion of the reactive O2
c to H2O2 + O2, the former being
subsequently detoxied by catalase.39 Buthionine sulfoximine
(BSO) provided a suitable attenuator of the reducing capacity of
the cell, as discussed further below, and has been previously
used in combination with PDT.40 Saporin (SAP) was the main
cytotoxin utilized since it is an ideal agent for investigating PCI
owing to its poor native uptake into the cell coupled with its
high toxicity once internalized and liberated into the
cytosol.5,41–46 The choice of TPPS2a as the photosensitizer, which
has been widely used in previous PCI studies as a prototype PCI
photosensitizer, is also attractive since it is not a substrate for
the ABCG2 eﬄux pumps that are responsible for chemotherapy
multidrug resistance.47
In the initial part of this work, the feasibility of using PCI for
treating 4T1 breast cancer cells was examined. In order for PCI
to function optimally, the PDT eﬀect should be sub-lethal,25870 | RSC Adv., 2019, 9, 25861–25874therefore preliminary studies were conducted to optimize the
treatment dosimetry. Pre-treatment of cells with photosensi-
tizer plus chemotherapeutic (SAP or MTX) prior to light expo-
sure is the basis of the ‘light-aer’ protocol that was mainly
employed in this study. This enables the co-localization of both
TPPS2a1,48,49 and chemotherapeutic agent within endosomes. As
shown in Fig. 3, we demonstrated that PCI could signicantly
enhance the cytotoxicity of saporin, in agreement with other PCI
studies.4 We then sought to investigate whether addition of BSO
could further enhance the eﬃcacy of PCI, following preliminary
studies of the eﬀect of BSO addition on PDT, based on the
hypothesis that PCI eﬃcacy can be manipulated by modulating
the intracellular redox environment. BSO is an irreversible
inhibitor of g-glutamylcysteine synthase that causes depletion
of GSH in tumours and normal tissues. Thanislass and
colleagues50 demonstrated that sustained treatment (several
days) using BSO in male rats resulted in chronic suppression of
GSH levels, which was associated with an overall reduction in
antioxidant defenses owing to diminishing activity of catalase,
superoxide dismutase, and glutathione peroxidase among other
scavengers of ROS. In this study, monochlorobimane (mBCl)
was chosen as a uorescent probe (Fig. 1) for intracellular
glutathione levels. The 4-fold reduction in the mBCl signal for
4T1 cells treated with BSO under the same conditions as used
for the PDT/PCI studies versus untreated cells supports previous
ndings51 where there was signicant suppression of GSH and
GSSG levels in 4T1 cells aer 48 h incubation with 5 mM BSO.
Supporting evidence for the role of BSO in enhancing theThis journal is © The Royal Society of Chemistry 2019
Paper RSC Advances
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
9 
A
ug
us
t 2
01
9.
 D
ow
nl
oa
de
d 
on
 9
/2
/2
01
9 
1:
23
:3
3 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlineoxidative capacity of a cell is seen in the lipid peroxidation
studies using a lipophilic C11 uorescence probe (Fig. 5, 6 and
Table 1). The C11 uorescence probe will however be present in
other membranes apart from the endolysosomes, and it was
also added aer light treatment in order to avoid PDT-induced
damage by singlet oxygen attack or photodegradation by the
light source. Although lipid hydroperoxides are relatively long-
lived, it has recently been proposed52 that they can be
degraded to lipid aldehydes via radical attack and in the case of
PDT by direct interaction between the hydroperoxides and
photoexcited sensitiser. This study also conrmed the close
correlation between photosensitised membrane permeabilisa-
tion and formation of lipid hydroperoxides.
BSO had minimal eﬀect on PDT using the ‘immediate’ illu-
mination protocol (Fig. 2A). However, following the 4 h chasing
period, BSO signicantly enhanced PDT for illumination dura-
tions >150 seconds (Fig. 2B), and an incremental increase in the
eﬀect of BSO on PDT was observed. During the 4 h chasing
period, dilution of the photosensitizer that is originally located
in the cell membrane takes place aer its dispersal into the
medium surrounding the cells. Therefore, the majority of the
remaining photosensitizer aer the chasing period is associ-
ated with endolysosomal membranes within the cell. The
signicant potentiation of photocytotoxicity by BSO at this
concentration therefore suggests that its oxidative enhance-
ment eﬀect promotes lipid peroxidation within photosensitized
endolysosomal membranes. This eﬀect may be further
enhanced by the suppressive eﬀect of BSO on GPX4, rendering
the cell more prone to the generation of lipid hydroperoxide.53
Consequently, BSO + PCI may enhance cell death via both
apoptosis and ferroptosis.
Co-incubation of BSO with the cytotoxin resulted in signi-
cantly enhanced PCI eﬃcacy in a synergistic manner.
Comparison of Fig. 3A with Fig. 2B, shows that PCI resulted in
progressively higher cell kill than PDT for illumination times up
to 300 s. Addition of BSO enhanced the eﬃcacy of PCI for illu-
mination times#150 seconds. At longer times the PDT eﬀect in
the presence of BSO is no longer sub-lethal therefore the eﬃcacy
enhancement of PCI over PDT is diﬃcult to estimate since the
MTT assay can be insensitive at low cell viability values.54
As shown in Fig. 3C, the eﬀect of prolonging the post treat-
ment duration from 24 h to 72 h was signicant and resulted in
increased PCI cytotoxicity for both single agent and combina-
tion PCI  BSO. The increased cell kill could represent multiple
mechanisms including prolonged time for saporin induced
killing. Saporin induces cell kill via apoptosis which is a slower
process than necrosis, therefore the lower viability measured at
the longer assay time aer illumination would be consistent
with apoptotic cell death. We have previously observed
improved cell kill at 96 h vs. 24 h using PCI in prostate cancer
cells lines using the same photosensitiser.55 The eﬀect of BSO is
consistent with amechanistic role for GSH in regulating the rate
of production and survival of ROS generated following the
activation of a photosensitizer. Consequently, GSH levels within
a cell are likely to have a signicant impact on the eﬃcacy of
both PDT and PCI. However, since PCI requires only a sub-lethal
PDT dose, the enhanced therapeutic eﬃcacy induced by BSOThis journal is © The Royal Society of Chemistry 2019will likely be greater for PCI than PDT which relies solely on ROS
generation. Furthermore, Berg and colleagues have demon-
strated that photo-induced rupture of endolysosomes using
PDT is a relatively ineﬃcient means of cell killing, thus the
eﬀect of BSO on PCI may be further enhanced compared to
PDT.56 Manipulation of GSH may therefore be an important
consideration when developing PCI protocols. The ability of
a cell to enhance its reducing capabilities has been implicated
in the development of drug resistance. Multi-drug resistant
MCF-7/ADR breast cancer cells were shown to be 30-65-fold
more resistant to doxorubicin than wild type and this was
associated with 23-fold elevated glutathione-S-transferase (GST)
activity within the cytoplasm.57 Additionally, levels of nuclear-
targeted GST were not only elevated in doxorubicin-resistant
cancer cells but dynamically rose in response to treatment;
the group concluded that GST protects DNA from anticancer
drugs.58 This suggests that the use of BSO in harness with PCI
for counteracting multidrug resistance could also be an inter-
esting concept to explore further.
We also investigated the eﬀect of antioxidants on PCI, as
shown in Fig. 7. Cells were treated with the amino acid L-histi-
dine (LH), which is known to scavenge singlet oxygen.21 Since
LH is a small molecule it should readily penetrate phospholipid
membranes and scavenge ROS generated within the
membranes. The dose-dependent reversal of PCI indicates that
the mechanism is in part consistent with the involvement of the
type II process with the photosensitiser-mediated generation of
1O2, which degrades the endolysosomal phospholipid
membranes. We also carried out studies using SOD, which is
a much larger molecule than LH, thus intramembrane and
intracellular eﬀects are likely not to be signicant. Nevertheless,
treatment with SOD elicited signicant inhibition of the PCI
eﬀect whereas no inhibition was found for PDT only. Further
studies with smaller SOD mimetics may be useful as previously
done for PDT.59,60 The ndings of the ROS scavenger experi-
ments add further weight to the importance of ROS generation
and survival in PDT and PCI. In the case of LH, it is important to
consider that a non-enzymatic anti-oxidant can potentially
enhance ROS production, and this was observed at higher
doses.
Drug combination experiments were performed (Fig. 4) to
model better the reality in clinical practice when cytotoxins are
rarely used in isolation. We found that combination PCI can be
signicantly more eﬀective than single-cytotoxin based PCI
using the ‘light ‘aer’ (LA) protocol, where the combination of
both agents resulted in a substantial increase in cytotoxicity,
compared to SAP-PCI or MTX-PCI alone BSO. The addition of
BSO to combination PCI resulted in 89% cell kill. In contrast,
the use of the light ‘before’ (LB) protocol elicited only a weak
enhancement in cytotoxicity. Themechanism of the LB protocol
is unclear but presumes that photooxidative damage to existing
endosomes prior to drug loading can enhance cytosolic
delivery. This could occur via fusing of partially damaged yet
still intact endosomes with new endosomes containing the
agents that form aer light exposure. These fused endosomes
may then become unstable and release the agents into theRSC Adv., 2019, 9, 25861–25874 | 25871
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View Article Onlinecytosol. It is possible that a larger light and/or BSO drug dose is
required for this protocol to be more eﬀective than we observed.
Combination PCI is an area that certainly requires further
evaluation in order to establish its relevance to clinical practice
in cancer therapeutics. This in vitro study has shown that PCI
can be used to facilitate the internalisation of two structurally
and mechanistically diﬀerent cytotoxins in unison and that this
is better than single-agent PCI alone.Conclusions
PCI is an emerging technology that is already demonstrating its
translational potential in clinical trials for the treatment of solid
cancers. The aim of this study was to investigate the inuence of
intracellular oxidation and reduction repertoire on the eﬃcacy
of TPPS2a mediated PCI of saporin and mitoxantrone adminis-
tered either as single agents or co-administered for combined
therapy. This study provides new insight into the importance of
the redox environment of a cell for PCI and oﬀers an eﬀective
means for optimizing drug delivery using this platform. Overall
the ndings are consistent with the hypothesis that the amount
of ROS required to liberate endocytosed drugs from their cyto-
solic vesicles in PCI is signicantly less than that required for
PDT-induced cell killing. Consequently, a relatively small
increase in the ROS-scavenging capacity of a cell may be suﬃ-
cient to inhibit the low ROS-burden for PCI but have relatively
little eﬀect on PDT. It would be interesting to determine
whether BSO can improve the selectivity of tumour damage
induced by PCI since tumours can exhibit enhanced levels of
GSH compared to normal tissue. The combination of cytotoxins
for PCI may further widen the therapeutic indices of the chosen
chemotherapeutic agents to enable lower dosages and further
reduce unwanted side-eﬀects.Author contributions
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